• An Erratum to this article was published on 16 November 2016

This article has been updated

Abstract

Genes and pathways in which inactivation dampens tissue inflammation present new opportunities for understanding the pathogenesis of common human inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis. We identified a mutation in the gene encoding the deubiquitination enzyme USP15 (Usp15L749R) that protected mice against both experimental cerebral malaria (ECM) induced by Plasmodium berghei and experimental autoimmune encephalomyelitis (EAE). Combining immunophenotyping and RNA sequencing in brain (ECM) and spinal cord (EAE) revealed that Usp15L749R-associated resistance to neuroinflammation was linked to dampened type I interferon responses in situ. In hematopoietic cells and in resident brain cells, USP15 was coexpressed with, and functionally acted together with the E3 ubiquitin ligase TRIM25 to positively regulate type I interferon responses and to promote pathogenesis during neuroinflammation. The USP15-TRIM25 dyad might be a potential target for intervention in acute or chronic states of neuroinflammation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 24 October 2016

    In the version of this article initially published online, the symbol for the gene encoding granzyme B was incorrect (Gmzb) in the text in the third paragraph of the fourth subsection of Results and Figure 5d, and the symbol for the gene encoding granzyme A was incorrect (Gmza) in Figure 6h. These should be Gzmb and Gzma, respectively. The errors have been corrected for the print, PDF and HTML versions of this article.

Accessions

Primary accessions

Gene Expression Omnibus

References

  1. 1.

    & Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol. 24, 491–499 (2003).

  2. 2.

    Inflammatory responses associated with the induction of cerebral malaria: lessons from experimental murine models. PLoS Pathog. 8, e1003045 (2012).

  3. 3.

    et al. Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol. Appl. Neurobiol. 25, 331–340 (1999).

  4. 4.

    & Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect. 4, 291–300 (2002).

  5. 5.

    et al. Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. Infect. Immun. 73, 4190–4197 (2005).

  6. 6.

    et al. Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar. J. 6, 147 (2007).

  7. 7.

    et al. Functional roles for C5a and C5aR but not C5L2 in the pathogenesis of human and experimental cerebral malaria. Infect. Immun. 82, 371–379 (2014).

  8. 8.

    et al. Host resistance to malaria: using mouse models to explore the host response. Mamm. Genome 22, 32–42 (2011).

  9. 9.

    et al. Protection against the mortality associated with disease models mediated by TNF and IFN-γ in mice lacking IFN regulatory factor-1. J. Immunol. 163, 6820–6826 (1999).

  10. 10.

    et al. Irf8-regulated genomic responses drive pathological inflammation during cerebral malaria. PLoS Pathog. 9, e1003491 (2013).

  11. 11.

    et al. Mouse ENU mutagenesis to understand immunity to infection: methods, selected examples, and perspectives. Genes (Basel) 5, 887–925 (2014).

  12. 12.

    et al. An N-ethyl-N-nitrosourea (ENU)-induced dominant negative mutation in the JAK3 kinase protects against cerebral malaria. PLoS One 7, e31012 (2012).

  13. 13.

    et al. THEMIS is required for pathogenesis of cerebral malaria and protection against pulmonary tuberculosis. Infect. Immun. 83, 759–768 (2015).

  14. 14.

    et al. CCDC88B is a novel regulator of maturation and effector functions of T cells during pathological inflammation. J. Exp. Med. 211, 2519–2535 (2014).

  15. 15.

    et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214–219 (2011).

  16. 16.

    et al. Multiple common variants for celiac disease influencing immune gene expression. Nat. Genet. 42, 295–302 (2010).

  17. 17.

    et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45, 1353–1360 (2013).

  18. 18.

    et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).

  19. 19.

    et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2014).

  20. 20.

    et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 7, e1002341 (2011).

  21. 21.

    , & Primary immunodeficiencies and inflammatory disease: a growing genetic intersection. Trends Immunol. 37, 126–140 (2016).

  22. 22.

    et al. The ubiquitin-specific protease USP15 promotes RIG-I-mediated antiviral signaling by deubiquitylating TRIM25. Sci. Signal. 7, ra3 (2014).

  23. 23.

    et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916–920 (2007).

  24. 24.

    et al. Susceptibility to lethal cerebral malaria is regulated by epistatic interaction between chromosome 4 (Berr6) and chromosome 1 (Berr7) loci in mice. Genes Immun. 14, 249–257 (2013).

  25. 25.

    et al. Solution structure of the human ubiquitin-specific protease 15 DUSP domain. J. Biol. Chem. 281, 5026–5031 (2006).

  26. 26.

    et al. The zinc finger of the CSN-associated deubiquitinating enzyme USP15 is essential to rescue the E3 ligase Rbx1. Curr. Biol. 15, 1217–1221 (2005).

  27. 27.

    , & Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol. 17, 243–250 (2007).

  28. 28.

    et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).

  29. 29.

    et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040–D1046 (2013).

  30. 30.

    , , & CSN controls NF-kappaB by deubiquitinylation of IkappaBalpha. EMBO J. 26, 1532–1541 (2007).

  31. 31.

    et al. The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy. Hum. Mol. Genet. 23, 5227–5242 (2014).

  32. 32.

    et al. Direct and indirect control of mitogen-activated protein kinase pathway-associated components, BRAP/IMP E3 ubiquitin ligase and CRAF/RAF1 kinase, by the deubiquitylating enzyme USP15. J. Biol. Chem. 287, 43007–43018 (2012).

  33. 33.

    et al. USP15 negatively regulates Nrf2 through deubiquitination of Keap1. Mol. Cell 51, 68–79 (2013).

  34. 34.

    et al. The U4/U6 recycling factor SART3 has histone chaperone activity and associates with USP15 to regulate H2B deubiquitination. J. Biol. Chem. 289, 8916–8930 (2014).

  35. 35.

    et al. USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat. Cell Biol. 13, 1368–1375 (2011).

  36. 36.

    et al. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat. Med. 18, 429–435 (2012).

  37. 37.

    et al. USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. Sci. Rep. 5, 14733 (2015).

  38. 38.

    et al. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat. Immunol. 15, 562–570 (2014).

  39. 39.

    et al. Ubiquitin-specific protease 15 negatively regulates virus-induced type I interferon signaling via catalytically-dependent and -independent mechanisms. Sci Rep. 5, 11220 (2015).

  40. 40.

    et al. Linear ubiquitin assembly complex negatively regulates RIG-I- and TRIM25-mediated type I interferon induction. Mol. Cell 41, 354–365 (2011).

  41. 41.

    et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat. Med. 20, 47–53 (2014).

  42. 42.

    , , & Innate sensing of malaria parasites. Nat. Rev. Immunol. 14, 744–757 (2014).

  43. 43.

    , , , & Interferon-mediated innate immune responses against malaria parasite liver stages. Cell Rep. 7, 436–447 (2014).

  44. 44.

    et al. IFNAR1 controls progression to cerebral malaria in children and CD8+ T cell brain pathology in Plasmodium berghei-infected mice. J. Immunol. 190, 5118–5127 (2013).

  45. 45.

    et al. Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA. Eur. J. Immunol. 43, 2683–2695 (2013).

  46. 46.

    et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35, 194–207 (2011).

  47. 47.

    et al. Pathological role of Toll-like receptor signaling in cerebral malaria. Int. Immunol. 19, 67–79 (2007).

  48. 48.

    et al. Murine cerebral malaria development is independent of toll-like receptor signaling. Am. J. Pathol. 170, 1640–1648 (2007).

  49. 49.

    et al. Genome-wide association study of lung function decline in adults with and without asthma. J. Allergy Clin. Immunol. 129, 1218–1228 (2012).

  50. 50.

    et al. Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor alpha. Proc. Natl. Acad. Sci. USA 96, 12027–12032 (1999).

  51. 51.

    et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417, 871–875 (2002).

  52. 52.

    et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J. Immunol. 180, 3746–3756 (2008).

  53. 53.

    & Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

  54. 54.

    & BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).

  55. 55.

    , & Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129, 1953–1971 (2006).

  56. 56.

    , , & Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).

  57. 57.

    et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).

  58. 58.

    , & featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).

  59. 59.

    & A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).

  60. 60.

    , & Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178–192 (2013).

  61. 61.

    et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34, 374–378 (2003).

  62. 62.

    , & Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).

  63. 63.

    et al. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J. Neurosci. 27, 1220–1228 (2007).

  64. 64.

    et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 60, 717–727 (2012).

Download references

Acknowledgements

We thank R. Van Bruggen, S. Gauthier, P. D'Arcy and G. Perreault for assistance in the ENU project, and C. Meunier for technical assistance. Supported by the Canadian Institutes of Health Research (MOP119342 and MOP133487 to P.G. and S.V.) and Amorchem (PT63088).

Author information

Affiliations

  1. Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

    • Sabrina Torre
    • , Gabriel A Leiva-Torres
    • , Jacek Majewski
    • , Mark Lathrop
    • , Silvia M Vidal
    •  & Philippe Gros
  2. McGill Center for Complex Traits, McGill University, Montreal, Quebec, Canada.

    • Sabrina Torre
    • , Maria J Polyak
    • , David Langlais
    • , Nassima Fodil
    • , James M Kennedy
    • , Irena Radovanovic
    • , Joanne Berghout
    • , Gabriel A Leiva-Torres
    • , Silvia M Vidal
    •  & Philippe Gros
  3. Department of Biochemistry, McGill University, Montreal, Quebec, Canada.

    • Maria J Polyak
    • , David Langlais
    • , Nassima Fodil
    • , James M Kennedy
    • , Irena Radovanovic
    • , Joanne Berghout
    •  & Philippe Gros
  4. Department of Microbiology, and Immunology, McGill University, Montreal, Quebec, Canada.

    • Connie M Krawczyk
  5. Department of Pediatrics, Faculty of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada.

    • Subburaj Ilangumaran
  6. Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.

    • Karen Mossman
  7. Department of Medicine, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

    • Chen Liang
  8. Institute for Neuropathology, University Clinic Freiburg, Freiburg, Germany.

    • Klaus-Peter Knobeloch
  9. Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

    • Luke M Healy
    •  & Jack Antel
  10. Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.

    • Nathalie Arbour
    •  & Alexandre Prat
  11. McGill University and Genome Quebec Innovation Center, McGill University, Montreal, Quebec, Canada.

    • Jacek Majewski
    •  & Mark Lathrop

Authors

  1. Search for Sabrina Torre in:

  2. Search for Maria J Polyak in:

  3. Search for David Langlais in:

  4. Search for Nassima Fodil in:

  5. Search for James M Kennedy in:

  6. Search for Irena Radovanovic in:

  7. Search for Joanne Berghout in:

  8. Search for Gabriel A Leiva-Torres in:

  9. Search for Connie M Krawczyk in:

  10. Search for Subburaj Ilangumaran in:

  11. Search for Karen Mossman in:

  12. Search for Chen Liang in:

  13. Search for Klaus-Peter Knobeloch in:

  14. Search for Luke M Healy in:

  15. Search for Jack Antel in:

  16. Search for Nathalie Arbour in:

  17. Search for Alexandre Prat in:

  18. Search for Jacek Majewski in:

  19. Search for Mark Lathrop in:

  20. Search for Silvia M Vidal in:

  21. Search for Philippe Gros in:

Contributions

S.T., M.L., J.M. and J.B. contributed to mutation identification. S.T. performed all of the PbA experiments. M.J.P. performed all of the EAE experiments. S.T. and M.J.P. performed biochemical work. I.R., J.M.K. and S.T. performed the immunophenotyping experiments. D.L. performed RNA sequencing analyses, and S.T. carried out validations by RT-qPCR. Primary cells from brain were provided and characterized by J.A., N.A., A.P., M.J.P. and L.M.H., with additional contribution from G.A.L.-T., S.I., K.M., C.L. and K.P.K. kindly provided gene knockout animals. S.T. performed Listeria experiments with guidance from C.M.K. N.F. performed BM transplant experiments. J.B., J.M. and M.L. performed analyses of exome sequences. P.G. and S.M.V. supervised the project, helped to design experiments and analyzed data. P.G., S.T., D.L., M.J.P. and N.F. wrote the first draft of the manuscript. All of the authors provided helpful comments on the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Philippe Gros.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–8

Excel files

  1. 1.

    Supplementary Table 1

    List of dys-regulated genes in Usp15L749R mutant mice undergoing ECM and EAE models of neuroinflammatory diseases, related to Fig. 4b.

  2. 2.

    Supplementary Table 2

    Detailed matrix of leading edge analysis clustering performed on ECM and EAE depleted gene signatures in Usp15L749R mutant mice, related to Fig. 5a.

  3. 3.

    Supplementary Table 3

    qPCR validation primers, related to Fig. 5c-f.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ni.3581

Further reading